Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Executive Changes Leadership BioPharmaceutical

Executives On The Move: Zymeworks, Novan and More

  • News

Executive Summary

Recent executive moves in the industry include C-suite changes at NervGen Pharma and Novan. Meanwhile, new directors were appointed at Zymeworks and Mirum Pharmaceuticals.

You may also be interested in...



Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.

BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.

Pharma vs The IRA — Industry Leaders React To Merck Lawsuit

Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.

Table

View full table

Topics

Tags:
Executive Changes Leadership BioPharmaceutical
Latest Headlines

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes

BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

See All
UsernamePublicRestriction

Register

SC148206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By